Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis ; volume:47 ; number:09 ; year:2015 ; pages:686-692
Hormone and metabolic research ; 47, Heft 09 (2015), 686-692
- Beteiligte Personen und Organisationen
-
Ojima, A.
Matsui, T.
Nishino, Y.
Nakamura, N.
Yamagishi, S.
- DOI
-
10.1055/s-0034-1395609
- URN
-
urn:nbn:de:101:1-2019050710321155990910
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ojima, A.
- Matsui, T.
- Nishino, Y.
- Nakamura, N.
- Yamagishi, S.
Ähnliche Objekte (12)
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
The effect of empagliflozin (sodium–glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
The effect of empagliflozin (sodium–glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?
Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Effects of the sodium-glucose cotransporter 2 inhibitors Canagliflozin, Dapagliflozin and Empagliflozin on endothelial barrier dysfunction : An in-vitro study
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy
The effect of empagliflozin (sodium–glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?